[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Y Huang, H Sun, H Yu, S Li, Q Zheng… - Antibody …, 2020 - academic.oup.com
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
Neutralizing antibodies for the treatment of COVID-19
Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …
main content Thank you for visiting nature.com. You are using a browser version with limited …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
P Schmidt, K Narayan, Y Li, CI Kaku… - Science Translational …, 2023 - science.org
Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …
Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …
have become a major concern in the containment of current pandemic. The variants …
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
NYL Pang, ASR Pang, VT Chow, DY Wang - Military Medical Research, 2021 - Springer
SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …